As of Friday close, Seelos Therapeutics Inc.’s (NASDAQ:SEEL) stock was down -$0.03, moving down -14.26 percent to $0.16. The average number of shares traded per day over the past five days has been 23,631,840 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.7588 fall in that time frame. In the last twenty days, the average volume was 6,422,615, while in the previous 50 days, it was 3,206,472.
Since last month, SEEL stock retreated -84.92%. Shares of the company fell to $0.1523 on 09/22/23, the lowest level in the past month. A 52-week high of $1.66 was reached on 08/03/23 after having rallying from a 52-week low of $0.19. Since the beginning of this year, SEEL’s stock price has dropped by -76.01% or -$0.5161, and marked a new high 23 times. However, the stock has declined by -90.19% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Financial Health
In the three months ended June 29, Seelos Therapeutics Inc.’s quick ratio stood at 0.20, while its current ratio was 0.20, showing that the company is not able to pay off its debt. Based on annual data, SEEL earned $70.92 million in gross profit.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. SEEL’s revenue rose 95.24% to $0.88 million during the quarter, while net income inched up to $0.42 million. While analysts expected Seelos Therapeutics Inc. to report -$0.09 quarterly earnings, the actual figure was -$0.22 per share, beating the consensus estimate by -144.40%. During the quarter, the company generated -$10.94 million in EBITDA. The liabilities of Seelos Therapeutics Inc. were 59.07 million at the end of its most recent quarter ended June 29, and its total debt was $15.34 million. The value of shareholders’ equity is $127.36 million.
Technical Picture
This quick technical analysis looks at Seelos Therapeutics Inc.’s (SEEL) price momentum. With a historical volatility rate of 588.29%, the RSI 9-day stood at 15.74% on 22 September.
With respect to its five-day moving average, the current Seelos Therapeutics Inc. price is down by -82.33% percent or -$0.7588. At present, SEEL shares trade -84.78% below its 20-day simple moving average and -76.39% percent below its 100-day simple moving average. However, the stock is currently trading approximately -87.75% below its SMA50 and -83.71% below its SMA200.
Stochastic coefficient K was 3.05% and Stochastic coefficient D was 13.14%, while ATR was 0.1496. Given the Stochastic reading of 1.11% for the 14-day period, the RSI (14) reading has been calculated as 18.86%. As of today, the MACD Oscillator reading stands at -0.4731, while the 14-day reading stands at -0.5829.
Analyst Ratings
ROTH Capital upgraded its rating on Seelos Therapeutics Inc. (NASDAQ: SEEL) to a Buy in a note to investors on September 27, 2021. The analysts firm previously had a Neutral rating on the stock.Seelos Therapeutics Inc. (SEEL) has been rated Overweight by analysts. According to 0 brokerage firms, SEEL is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Seelos Therapeutics Inc. stock as buy, with 2 recommending it as overweight.
With a median target price of $2.00, the current consensus forecast for the stock is $1.00 – $4.00. Based on these forecasts, analysts predict Seelos Therapeutics Inc. (SEEL) will achieve an average price target of $2.33.
